Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)
Glossary on
off
Printer Friendly Page Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)

Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)

Clinicaltrials.gov identifier:
NCT04109066


Newly-diagnosed, non-metastatic, ER-positive, HER2-negative breast cancer

Study Contact Information:

For more information about the study, visit:
bmsstudyconnect.com/us/en/clinical-trials/NCT04109066.html

Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)

About the Study

The CA209-7FL clinical trial is researching if a study drug combined with pre-surgery chemotherapy, surgery, and post-surgery endocrine therapy could be safe, effective, and improve outcomes for people with ER+, HER-negative breast cancer. This will be compared to a group that receives a in addition to the same pre-surgery chemotherapy, surgery, and post-surgery endocrine therapy standard of care. NOTE: This study is no longer enrolling patients. 

 

For more information about the study, visit: https://www.bmsstudyconnect.com/us/en/clinical-trials/NCT04109066.html

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is Not Open To:

NOTE: This study is no longer enrolling patients.